Baseline characteristics of the nateglinide and valsartan impaired glucose tolerance outcomes research (NAVIGATOR) trial population: comparison with other diabetes prevention trials

Henry Krum, John McMurray, Edward Horton, Teresa Gerlock, Bjoern Holzhauer, Lineke Zuurman, Steven Haffner, M Bethel, Rury Holman, Robert Califf

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)

Abstract

The Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial is exploring two pharmacological strategies (nateglinide and valsartan, both alone and in combination) in the prevention of overt diabetes mellitus (DM) and the reduction of cardiovascular disease (CVD) in subjects at high risk for these events.
Original languageEnglish
Pages (from-to)124 - 132
Number of pages9
JournalCardiovascular Therapeutics
Volume28
Issue number2
DOIs
Publication statusPublished - 2010

Cite this